FDA approves therapy for first-line treatment of advanced NSCLC


FDA has approved paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (Abraxane, Celgene) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.